Market Place
Sourcing Support
All News #Library
Biotech
Cerevance To Unveil Positive Phase 2 Solengepras Data
09 Apr 2026 //
GLOBENEWSWIRE
Cerevance To Unveil Solengepras Phase 2 Results In Parkinson
10 Mar 2026 //
GLOBENEWSWIRE
Cerevance To Present At TD Cowen Health Care Conference
23 Feb 2026 //
GLOBENEWSWIRE
Cerevance Joins RBC Capital Markets 2025 Healthcare Conference
01 Dec 2025 //
GLOBENEWSWIRE
Cerevance To Showcase Solengepras In Parkinson`s At PSG Meeting
24 Nov 2025 //
GLOBENEWSWIRE
Cerevance Joins TD Cowen Summit On Obesity Treatments
17 Nov 2025 //
GLOBENEWSWIRE
Cerevance Reports Positive Phase 1 Results for CVN293 at AAN 2025
08 Apr 2025 //
GLOBENEWSWIRE
Cerevance Presents Phase 2 ASCEND Trial Results at AD/PD 2025
01 Apr 2025 //
GLOBENEWSWIRE
Cerevance Doses First Patient in Ph 3 ARISE Trial for Parkinson’s
18 Nov 2024 //
GLOBENEWSWIRE
Cerevance To Join Panel At Fierce Biotech Summit 2024
23 Sep 2024 //
GLOBENEWSWIRE
Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Letters
15 Feb 2024 //
GLOBENEWSWIRE
Cerevance to Participate at the Wells Fargo 2023 Private Biotech Symposium
25 Oct 2023 //
GLOBENEWSWIRE
Cerevance to Participate at the 3rd Annual Needham Biotech Private Company Forum
10 Oct 2023 //
GLOBENEWSWIRE
Fierce Biotech Names Cerevance a €œFierce 15€ Biotech Company of 2023
28 Aug 2023 //
GLOBENEWSWIRE
Cerevance Announces Oral Presentation of Ph 1 Data on CVN766 at (ASCP)
16 May 2023 //
GLOBENEWSWIRE
Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766
09 Jan 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.